Every quarter we look across our coverage to identify the signals that matter - not just which companies raised money, but what the pattern of activity tells us about where the industry is heading. Q1 2026 was one of the most active quarters we’ve covered in years. But the volume isn’t the story. The story is what the activity reveals about the structural shifts underway.
Here are the five themes that defined the quarter.
1. From Tracking to Diagnostics
The women’s health industry spent a decade building apps that log symptoms. What’s happening now is a shift toward generating clinically actionable data - and Q1 made that visible across multiple fronts.
The most striking signal was the convergence around menstrual blood as a diagnostic medium. In the space of a few weeks, Diamens raised funding for a PCR-based endometriosis test using menstrual blood, Endometrics won the NIH’s $600,000 first prize for its menstrual blood diagnostic platform, and SGS partnered with theblood to bring independent validation to the field. Three separate companies, three different scientific approaches, all advancing simultaneously. When multiple groups converge on the same sample type from different angles, it’s no longer an experiment - it’s a category forming.
Beyond menstrual blood, the same dynamic played out in other areas. WHOOP launched a women’s health blood biomarker panel with 11 female-specific markers spanning cycle regulation, perimenopause, thyroid function, and bone health - a consumer wearable company moving into clinical-grade testing. Clue received its largest-ever investment from Verdane, with the capital earmarked for healthcare partnerships and clinical research, not just app features. And Pregnolia secured $4.4 million from the European Innovation Council for its cervical stiffness device - a novel biomarker for preterm birth prediction.
The underlying shift: Women’s health data is crossing from informational to medically useful. The next wave of products won’t just tell women what’s happening in their bodies - they’ll generate data that changes clinical decisions.
2. The Rebundling
The first wave of women’s health innovation unbundled everything into point solutions - a fertility app here, a menopause platform there, a pregnancy tracker somewhere else. Q1 showed that trend reversing.
Maven Clinic launched a direct-to-consumer platform combining fertility care, GLP-1 management, and hormone care in a single offering - then followed it with Maven Intelligence, an AI orchestration layer that connects all of it across the care journey. Sword Health expanded Bloom from a pelvic health solution into a full life-stage women’s health platform for employers, adding menopause, fertility, and pregnancy programs. Kindbody added pregnancy support, menopause, and men’s health to what was previously a fertility-focused offering. And Midi Health reached unicorn status with a $100 million Series D, doing integrated midlife care across OB-GYN, cardiology, endocrinology, sleep, and mood disorders.
The underlying shift: The biology is connected across life stages, and the platforms are finally reflecting that. A woman’s pregnancy history informs her cardiovascular risk. Her hormonal patterns in her 30s are relevant to her perimenopause experience in her 40s. The companies winning are the ones that treat women’s health as a continuous journey rather than a series of disconnected episodes.
3. Outcomes Data as the Price of Entry
Capital in Q1 flowed disproportionately toward companies that could prove measurable impact - not just engagement or user growth, but hard clinical and cost outcomes.
The most concentrated example was the doula care space. In a single week, three doula-focused startups - Nadia Care ($12M), Malama Health ($9.2M), and Flourish Care ($5.7M) - raised a combined $27 million, all serving Medicaid populations and all leading with outcomes data: 60% reductions in NICU days, 38% lower preterm birth rates, 40% reduction in postpartum diabetes. (We covered the significance of that cluster in detail in our separate analysis of the doula care trend.) But the pattern extends beyond maternal care. Midi’s unicorn valuation was built on insurance-covered care. Maven’s pitch to employers centers on $9,600 saved per birth. The era of funding women’s health companies on mission alone is over. What unlocks capital now is proof that the model delivers measurable results.
The underlying shift: The question investors and payers are asking has changed. It’s no longer “Is this a real category?” It’s “Show me the numbers.” The companies that can demonstrate reduced complications, lower costs, and better clinical endpoints are the ones attracting serious capital - and the ones that can’t are being left behind.
4. Pharma Is Buying the Science
Novartis acquired a next-generation breast cancer drug from Synnovation Therapeutics in a deal worth up to $3 billion - $2 billion upfront - targeting the 40% of women with HR+/HER2- breast cancer who carry PIK3CA mutations. Gedeon Richter acquired Celmatix’s women’s health drug discovery portfolio, adding three programs spanning fertility, endometriosis, and ovarian aging. Sensei Biotherapeutics acquired Faeth Therapeutics alongside a $200 million raise, advancing therapies for endometrial and breast cancer.
These aren’t startups buying startups. These are established pharmaceutical and medtech companies acquiring high-value intellectual property in women’s health because it’s faster and lower-risk than building in-house R&D from scratch.
The underlying shift: Big pharma is no longer treating women’s health as peripheral. When a company like Novartis writes a $2 billion check for a breast cancer drug, when Gedeon Richter buys an entire fertility and reproductive health drug discovery pipeline - that’s the industry’s biggest players validating the commercial value of women’s health science. The acquisition wave signals that the IP coming out of women’s health R&D is now considered strategically valuable by the companies that drive most of global drug development.
5. Public and Institutional Money Is Arriving
One of the quieter but most significant signals of Q1 was the breadth of non-venture capital flowing into women’s health. The German government invested €12 million into non-hormonal contraception research. The European Innovation Council backed Pregnolia through one of Europe’s most competitive deep-tech funding programs. The NIH awarded Endometrics its top prize for endometriosis diagnostics. Malama Health’s seed round included a $2.3 million NIH grant and $900,000 in California state funding alongside venture capital. And 28x launched with backing from the Philips Foundation, building privacy-first period tracking infrastructure with mission-aligned rather than purely commercial capital.
The underlying shift: Government agencies, institutional funders, and mission-driven capital are entering women’s health in ways they weren’t two years ago. This matters because public funding carries a different kind of validation - it signals that the problems being addressed are considered not just commercially viable but socially necessary. It also reduces the dependence on venture capital as the sole engine of innovation in the space, which has historically created blind spots around the categories and populations that don’t fit a traditional VC return profile.
The Through-Line
If there is a single thread connecting all five of these themes, it’s this: Women’s health is becoming infrastructure. Not an add-on, not a wellness category, not a perk - but a permanent, integrated part of how healthcare is delivered, funded, and measured.
The diagnostic tools are generating clinical-grade data. The platforms are connecting life stages into continuous care. The care models are proving ROI to payers. Pharma is buying the science. And governments are funding the research. Each of these shifts reinforces the others. The companies and investors that recognized this early are the ones defining what Q1 looked like - and what the rest of 2026 will build on.
